← Back to Patent Explorer
US4246264A Expired / Lapsed US ⏱️ 0.0 years remaining

Treatment of hyperuricaemia with etofylline clofibrate

Assignee: Ludwig Merckle GmbH and Co KG Chem Pharm Fabrik
•
Filing: 1980-01-17
•
Granted: 1981-01-20
•
Expires: 2000-01-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The use of etofylline clofibrate for the treatment of elevated serum levels of uric acid in humans is disclosed.

Inventors

  • 👤 Gunter Metz
  • 👤 Manfred Specker

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 18:30
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 39 words
A process for the treatment of a host animal which is afflicted with hyperuricaemia which comprises administering to said animal an amount sufficient to lower the serum uric acid level of said host animal, a drug comprising etofylline clofibrate.
Claim 2
Dependent Claim 39 words
A process for the treatment of a host animal which is afflicted with hyperuricaemia which comprises administering to said animal an amount sufficient to lower the serum uric acid level of said host animal, a drug comprising etofylline clofibrate.
Claim 3
Dependent Claim 15 words
A process as defined in claim 1 wherein said host animal is a human being.
Claim 4
Dependent Claim 22 words
A process as defined in claim 2 wherein said drug is administered in the form of a soft or hard gelatin capsule.
Claim 5
Dependent Claim 20 words
A process as defined in claim 2 wherein said drug is administered in a dose of 250 to 1250 mg./day.
Claim 6
Dependent Claim 20 words
A process as defined in claim 2 wherein said drug is administered in a dose of 500 to 750 mg./day.
Claim 7
Dependent Claim 21 words
A process as defined in claim 2 wherein said drug is administered in a single dose of 250 to 600 mg./unit.
Claim 8
Dependent Claim 21 words
A process as defined in claim 2 wherein said drug is administered in a single dose of 250 to 300 mg./unit.

References Cited (Backward Citations)

US3984413A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1984-01-20 1984-07-21 1985-01-20 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1988-01-20 1988-07-21 1989-01-20 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1992-01-20 1992-07-21 1993-01-20 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag